Hosted on MSN2mon
Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other small-cap biotech stocks. The biotechnology sector is expanding ...
Scholar Rock's COO & CFO sells shares worth $554,188
This transaction was a mandatory sale to cover tax obligations associated with the vesting of restricted stock units (RSUs), as stipulated by Scholar Rock's equity incentive plans. These RSUs were ...
Yahoo Finance2d
Scholar Rock Holding Corporation (SRRK)
CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...
SMA14d
Scholar Rock asks FDA to approve apitegromab for SMA
Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.
ETF Daily News24d
Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts
Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have received an average recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat reports.
Business Wire4d
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
ETF Daily News1mon
Scholar Rock Holding Corporation Furnishes Presentation for J.P. Morgan Healthcare Conference
Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and ...
Seeking Alpha15d
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".
Business Insider16d
Scholar Rock Names Lisa Wyman As Chief Technical And Quality Officer
(RTTNews) - Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, Wednesday announced the appointment ...
Business Wire16d
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Yahoo Finance28d
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., January 17, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...